<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<!-- 2019-01-20 Sun 23:05 -->
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>&lrm;</title>
<meta name="generator" content="Org mode" />
<meta name="author" content="zds" />
<style type="text/css">
 <!--/*--><![CDATA[/*><!--*/
  .title  { text-align: center;
             margin-bottom: .2em; }
  .subtitle { text-align: center;
              font-size: medium;
              font-weight: bold;
              margin-top:0; }
  .todo   { font-family: monospace; color: red; }
  .done   { font-family: monospace; color: green; }
  .priority { font-family: monospace; color: orange; }
  .tag    { background-color: #eee; font-family: monospace;
            padding: 2px; font-size: 80%; font-weight: normal; }
  .timestamp { color: #bebebe; }
  .timestamp-kwd { color: #5f9ea0; }
  .org-right  { margin-left: auto; margin-right: 0px;  text-align: right; }
  .org-left   { margin-left: 0px;  margin-right: auto; text-align: left; }
  .org-center { margin-left: auto; margin-right: auto; text-align: center; }
  .underline { text-decoration: underline; }
  #postamble p, #preamble p { font-size: 90%; margin: .2em; }
  p.verse { margin-left: 3%; }
  pre {
    border: 1px solid #ccc;
    box-shadow: 3px 3px 3px #eee;
    padding: 8pt;
    font-family: monospace;
    overflow: auto;
    margin: 1.2em;
  }
  pre.src {
    position: relative;
    overflow: visible;
    padding-top: 1.2em;
  }
  pre.src:before {
    display: none;
    position: absolute;
    background-color: white;
    top: -10px;
    right: 10px;
    padding: 3px;
    border: 1px solid black;
  }
  pre.src:hover:before { display: inline;}
  /* Languages per Org manual */
  pre.src-asymptote:before { content: 'Asymptote'; }
  pre.src-awk:before { content: 'Awk'; }
  pre.src-C:before { content: 'C'; }
  /* pre.src-C++ doesn't work in CSS */
  pre.src-clojure:before { content: 'Clojure'; }
  pre.src-css:before { content: 'CSS'; }
  pre.src-D:before { content: 'D'; }
  pre.src-ditaa:before { content: 'ditaa'; }
  pre.src-dot:before { content: 'Graphviz'; }
  pre.src-calc:before { content: 'Emacs Calc'; }
  pre.src-emacs-lisp:before { content: 'Emacs Lisp'; }
  pre.src-fortran:before { content: 'Fortran'; }
  pre.src-gnuplot:before { content: 'gnuplot'; }
  pre.src-haskell:before { content: 'Haskell'; }
  pre.src-hledger:before { content: 'hledger'; }
  pre.src-java:before { content: 'Java'; }
  pre.src-js:before { content: 'Javascript'; }
  pre.src-latex:before { content: 'LaTeX'; }
  pre.src-ledger:before { content: 'Ledger'; }
  pre.src-lisp:before { content: 'Lisp'; }
  pre.src-lilypond:before { content: 'Lilypond'; }
  pre.src-lua:before { content: 'Lua'; }
  pre.src-matlab:before { content: 'MATLAB'; }
  pre.src-mscgen:before { content: 'Mscgen'; }
  pre.src-ocaml:before { content: 'Objective Caml'; }
  pre.src-octave:before { content: 'Octave'; }
  pre.src-org:before { content: 'Org mode'; }
  pre.src-oz:before { content: 'OZ'; }
  pre.src-plantuml:before { content: 'Plantuml'; }
  pre.src-processing:before { content: 'Processing.js'; }
  pre.src-python:before { content: 'Python'; }
  pre.src-R:before { content: 'R'; }
  pre.src-ruby:before { content: 'Ruby'; }
  pre.src-sass:before { content: 'Sass'; }
  pre.src-scheme:before { content: 'Scheme'; }
  pre.src-screen:before { content: 'Gnu Screen'; }
  pre.src-sed:before { content: 'Sed'; }
  pre.src-sh:before { content: 'shell'; }
  pre.src-sql:before { content: 'SQL'; }
  pre.src-sqlite:before { content: 'SQLite'; }
  /* additional languages in org.el's org-babel-load-languages alist */
  pre.src-forth:before { content: 'Forth'; }
  pre.src-io:before { content: 'IO'; }
  pre.src-J:before { content: 'J'; }
  pre.src-makefile:before { content: 'Makefile'; }
  pre.src-maxima:before { content: 'Maxima'; }
  pre.src-perl:before { content: 'Perl'; }
  pre.src-picolisp:before { content: 'Pico Lisp'; }
  pre.src-scala:before { content: 'Scala'; }
  pre.src-shell:before { content: 'Shell Script'; }
  pre.src-ebnf2ps:before { content: 'ebfn2ps'; }
  /* additional language identifiers per "defun org-babel-execute"
       in ob-*.el */
  pre.src-cpp:before  { content: 'C++'; }
  pre.src-abc:before  { content: 'ABC'; }
  pre.src-coq:before  { content: 'Coq'; }
  pre.src-groovy:before  { content: 'Groovy'; }
  /* additional language identifiers from org-babel-shell-names in
     ob-shell.el: ob-shell is the only babel language using a lambda to put
     the execution function name together. */
  pre.src-bash:before  { content: 'bash'; }
  pre.src-csh:before  { content: 'csh'; }
  pre.src-ash:before  { content: 'ash'; }
  pre.src-dash:before  { content: 'dash'; }
  pre.src-ksh:before  { content: 'ksh'; }
  pre.src-mksh:before  { content: 'mksh'; }
  pre.src-posh:before  { content: 'posh'; }
  /* Additional Emacs modes also supported by the LaTeX listings package */
  pre.src-ada:before { content: 'Ada'; }
  pre.src-asm:before { content: 'Assembler'; }
  pre.src-caml:before { content: 'Caml'; }
  pre.src-delphi:before { content: 'Delphi'; }
  pre.src-html:before { content: 'HTML'; }
  pre.src-idl:before { content: 'IDL'; }
  pre.src-mercury:before { content: 'Mercury'; }
  pre.src-metapost:before { content: 'MetaPost'; }
  pre.src-modula-2:before { content: 'Modula-2'; }
  pre.src-pascal:before { content: 'Pascal'; }
  pre.src-ps:before { content: 'PostScript'; }
  pre.src-prolog:before { content: 'Prolog'; }
  pre.src-simula:before { content: 'Simula'; }
  pre.src-tcl:before { content: 'tcl'; }
  pre.src-tex:before { content: 'TeX'; }
  pre.src-plain-tex:before { content: 'Plain TeX'; }
  pre.src-verilog:before { content: 'Verilog'; }
  pre.src-vhdl:before { content: 'VHDL'; }
  pre.src-xml:before { content: 'XML'; }
  pre.src-nxml:before { content: 'XML'; }
  /* add a generic configuration mode; LaTeX export needs an additional
     (add-to-list 'org-latex-listings-langs '(conf " ")) in .emacs */
  pre.src-conf:before { content: 'Configuration File'; }

  table { border-collapse:collapse; }
  caption.t-above { caption-side: top; }
  caption.t-bottom { caption-side: bottom; }
  td, th { vertical-align:top;  }
  th.org-right  { text-align: center;  }
  th.org-left   { text-align: center;   }
  th.org-center { text-align: center; }
  td.org-right  { text-align: right;  }
  td.org-left   { text-align: left;   }
  td.org-center { text-align: center; }
  dt { font-weight: bold; }
  .footpara { display: inline; }
  .footdef  { margin-bottom: 1em; }
  .figure { padding: 1em; }
  .figure p { text-align: center; }
  .equation-container {
    display: table;
    text-align: center;
    width: 100%;
  }
  .equation {
    vertical-align: middle;
  }
  .equation-label {
    display: table-cell;
    text-align: right;
    vertical-align: middle;
  }
  .inlinetask {
    padding: 10px;
    border: 2px solid gray;
    margin: 10px;
    background: #ffffcc;
  }
  #org-div-home-and-up
   { text-align: right; font-size: 70%; white-space: nowrap; }
  textarea { overflow-x: auto; }
  .linenr { font-size: smaller }
  .code-highlighted { background-color: #ffff00; }
  .org-info-js_info-navigation { border-style: none; }
  #org-info-js_console-label
    { font-size: 10px; font-weight: bold; white-space: nowrap; }
  .org-info-js_search-highlight
    { background-color: #ffff00; color: #000000; font-weight: bold; }
  .org-svg { width: 90%; }
  /*]]>*/-->
</style>
<script type="text/javascript">
/*
@licstart  The following is the entire license notice for the
JavaScript code in this tag.

Copyright (C) 2012-2018 Free Software Foundation, Inc.

The JavaScript code in this tag is free software: you can
redistribute it and/or modify it under the terms of the GNU
General Public License (GNU GPL) as published by the Free Software
Foundation, either version 3 of the License, or (at your option)
any later version.  The code is distributed WITHOUT ANY WARRANTY;
without even the implied warranty of MERCHANTABILITY or FITNESS
FOR A PARTICULAR PURPOSE.  See the GNU GPL for more details.

As additional permission under GNU GPL version 3 section 7, you
may distribute non-source (e.g., minimized or compacted) forms of
that code without the copy of the GNU GPL normally required by
section 4, provided you include this license notice and a URL
through which recipients can access the Corresponding Source.


@licend  The above is the entire license notice
for the JavaScript code in this tag.
*/
<!--/*--><![CDATA[/*><!--*/
 function CodeHighlightOn(elem, id)
 {
   var target = document.getElementById(id);
   if(null != target) {
     elem.cacheClassElem = elem.className;
     elem.cacheClassTarget = target.className;
     target.className = "code-highlighted";
     elem.className   = "code-highlighted";
   }
 }
 function CodeHighlightOff(elem, id)
 {
   var target = document.getElementById(id);
   if(elem.cacheClassElem)
     elem.className = elem.cacheClassElem;
   if(elem.cacheClassTarget)
     target.className = elem.cacheClassTarget;
 }
/*]]>*///-->
</script>
</head>
<body>
<div id="content">
<div id="outline-container-org94bc477" class="outline-2">
<h2 id="org94bc477"><span class="section-number-2">1</span> Subjective</h2>
<div class="outline-text-2" id="text-1">
</div>
<div id="outline-container-orgf0efe4f" class="outline-3">
<h3 id="orgf0efe4f"><span class="section-number-3">1.1</span> Patient</h3>
<div class="outline-text-3" id="text-1-1">
<p>
Hilda Alvarez (“patient”) is a 78 year old Dominican female.
</p>
</div>
</div>
<div id="outline-container-org0274128" class="outline-3">
<h3 id="org0274128"><span class="section-number-3">1.2</span> Chief complaint</h3>
<div class="outline-text-3" id="text-1-2">
<ul class="org-ul">
<li>shortness of breath</li>
<li>cough</li>
<li>fever</li>
</ul>
</div>
</div>
<div id="outline-container-org019855f" class="outline-3">
<h3 id="org019855f"><span class="section-number-3">1.3</span> History of present illness</h3>
<div class="outline-text-3" id="text-1-3">
<p>
Patient is a 78 year old female was seen at the urgent care center on 1/18/19 secondary to persistent cough and intermittent wheezing. In the emergency room, the patient was felt to have a small left lower lobe pneumonia and was placed on Augmentin and Azithromycin for generalized body aches that began yesterday. The patient, at that time, had no shortness of breath and no chest pain. She presents today (1/21/19) to the emergency room department feeling quite fatigued, SOB, with recurrent myalgias over the course of the last few days since her visit to urgent care. She is now complaining of productive cough with increased sputum volume, subjective fevers.
</p>
</div>
</div>
<div id="outline-container-org498eff9" class="outline-3">
<h3 id="org498eff9"><span class="section-number-3">1.4</span> Social history</h3>
<div class="outline-text-3" id="text-1-4">
<p>
Former 5 PPD smoker for 30 years; quit 1 year ago
</p>
</div>
</div>
<div id="outline-container-org9a7500f" class="outline-3">
<h3 id="org9a7500f"><span class="section-number-3">1.5</span> Family history</h3>
<div class="outline-text-3" id="text-1-5">
<ul class="org-ul">
<li>congestive heart failure</li>
<li>congestive heart disease</li>
</ul>
</div>
</div>
<div id="outline-container-org929281f" class="outline-3">
<h3 id="org929281f"><span class="section-number-3">1.6</span> Allergies</h3>
<div class="outline-text-3" id="text-1-6">
<p>
No known drug allergies
</p>
</div>
</div>
</div>
<div id="outline-container-org48b9ecd" class="outline-2">
<h2 id="org48b9ecd"><span class="section-number-2">2</span> Objective</h2>
<div class="outline-text-2" id="text-2">
</div>
<div id="outline-container-org38790df" class="outline-3">
<h3 id="org38790df"><span class="section-number-3">2.1</span> Past medical history</h3>
<div class="outline-text-3" id="text-2-1">
<ul class="org-ul">
<li>moderate COPD</li>
<li>paroxysmal atrial fibrillation</li>
<li>pulmonary function</li>
</ul>
</div>
</div>
<div id="outline-container-org04f394a" class="outline-3">
<h3 id="org04f394a"><span class="section-number-3">2.2</span> Family history</h3>
<div class="outline-text-3" id="text-2-2">
<p>
congenital heart disease and congestive heart failure
</p>
</div>
</div>
<div id="outline-container-org5b23010" class="outline-3">
<h3 id="org5b23010"><span class="section-number-3">2.3</span> Immunization history</h3>
<div class="outline-text-3" id="text-2-3">
<p>
Up to date per GRITS including influenza shot on December 23, 2018
</p>
</div>
</div>
<div id="outline-container-org1893cef" class="outline-3">
<h3 id="org1893cef"><span class="section-number-3">2.4</span> Medications</h3>
<div class="outline-text-3" id="text-2-4">
<ul class="org-ul">
<li>Amoxicillin-pot clavulanate Orally 875-125 mg Dose: 1 tablet(s) 2 Times A Day (started on 1/18/19 for suspected pneumonia)</li>
<li>Azithromycin Orally 250 mg Dose: 1 tablet(s) Daily (started on 1/18/19 for suspected pneumonia)</li>
<li>Amiodarone Oral Dose: 100 mg Every day for atrial fibrillation</li>
<li>Venlafaxine Oral Dose: 75 mg Every morning for anxiety and depression</li>
<li>Coumadin Dose: 2.5 mg MWF and 1.25mg TTSS for anticoagulation</li>
<li>Albuterol 1 puff 4 times a day as needed. for cough, wheezing, and/or SOB</li>
<li>Salmeterol-Fluticasone DPI (Advair Diskus) 50/250 1 puff BID. for COPD</li>
</ul>
</div>
</div>
<div id="outline-container-org60ff50f" class="outline-3">
<h3 id="org60ff50f"><span class="section-number-3">2.5</span> Vital signs</h3>
<div class="outline-text-3" id="text-2-5">
<p>
Height: 5'2"
Weight: 180 lbs
</p>

<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />

<col  class="org-left" />

<col  class="org-right" />

<col  class="org-right" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">Time</th>
<th scope="col" class="org-left">BP</th>
<th scope="col" class="org-right">Pulse</th>
<th scope="col" class="org-left">PulseOx</th>
<th scope="col" class="org-right">Respiration</th>
<th scope="col" class="org-right">Temp</th>
<th scope="col" class="org-right">Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left">1/22 01:47</td>
<td class="org-left">120/70</td>
<td class="org-right">92</td>
<td class="org-left">3L</td>
<td class="org-right">38</td>
<td class="org-right">101.8</td>
<td class="org-right">0</td>
</tr>

<tr>
<td class="org-left">1/22 00:21</td>
<td class="org-left">120/76</td>
<td class="org-right">92</td>
<td class="org-left">2L</td>
<td class="org-right">36</td>
<td class="org-right">102.0</td>
<td class="org-right">0</td>
</tr>

<tr>
<td class="org-left">1/21 19:33</td>
<td class="org-left">132/69</td>
<td class="org-right">92</td>
<td class="org-left">2L</td>
<td class="org-right">34</td>
<td class="org-right">102.1</td>
<td class="org-right">5</td>
</tr>

<tr>
<td class="org-left">1/21 15:116</td>
<td class="org-left">&#xa0;</td>
<td class="org-right">99</td>
<td class="org-left">2L</td>
<td class="org-right">&#xa0;</td>
<td class="org-right">&#xa0;</td>
<td class="org-right">&#xa0;</td>
</tr>
</tbody>
</table>

<p>
HEENT: PERRLA, yellow-green nasal discharge, nasal membranes mild erythema
Neck/Lymph Nodes: Supple; no lymphadenopathy or thyromegaly
Lungs/Thorax: dullness to percussion, increased tactile fremitus whisper
pectoriloquy and egophony. Tachypneic, labored breathing; inspiratory crackles
during lung expansion throughout right lung fields; decreased breath sounds in right
middle and right lower lung fields
CV: Audible S1 and S2; tachycardic with irregular rate and rhythm; no MRG
Abd: NTND; positive bowel sounds
Extremities: No CCE; 5/5 grip strength; 2+ pulses bilaterally
Neuro: A&amp;O x 3; CN II-XII intact
</p>
</div>
</div>
<div id="outline-container-org50b0500" class="outline-3">
<h3 id="org50b0500"><span class="section-number-3">2.6</span> Labs</h3>
<div class="outline-text-3" id="text-2-6">
</div>
<div id="outline-container-org4872279" class="outline-4">
<h4 id="org4872279"><span class="section-number-4">2.6.1</span> Blood metabolic panel</h4>
<div class="outline-text-4" id="text-2-6-1">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">Measurement</th>
<th scope="col" class="org-left">Value</th>
<th scope="col" class="org-right">Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left"><b>BUN</b></td>
<td class="org-left">25  mg/dL</td>
<td class="org-right">7-20</td>
</tr>

<tr>
<td class="org-left"><b>glucose</b></td>
<td class="org-left">101  mg/dL</td>
<td class="org-right">60-99</td>
</tr>

<tr>
<td class="org-left"><b>creatinine</b></td>
<td class="org-left">1.3  mg/dL</td>
<td class="org-right">1.3</td>
</tr>

<tr>
<td class="org-left">sodium</td>
<td class="org-left">137  mmol/L</td>
<td class="org-right">135-145</td>
</tr>

<tr>
<td class="org-left">potassium</td>
<td class="org-left">4.3  mmol/L</td>
<td class="org-right">3.5-5.5</td>
</tr>

<tr>
<td class="org-left">chloride</td>
<td class="org-left">103  mmol/L</td>
<td class="org-right">99-109</td>
</tr>

<tr>
<td class="org-left">CO₂</td>
<td class="org-left">25.5  mmol/L</td>
<td class="org-right">24.0-31.0</td>
</tr>

<tr>
<td class="org-left">calcium</td>
<td class="org-left">9.7  mg/dL</td>
<td class="org-right">8.5-10.8</td>
</tr>

<tr>
<td class="org-left">anion gap</td>
<td class="org-left">9</td>
<td class="org-right">3-11</td>
</tr>

<tr>
<td class="org-left">magnesium</td>
<td class="org-left">1.9  mg/dL</td>
<td class="org-right">1.8-2.5</td>
</tr>

<tr>
<td class="org-left">lactic acid</td>
<td class="org-left">1.6</td>
<td class="org-right">0.5-2.0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="outline-container-orga07f54e" class="outline-4">
<h4 id="orga07f54e"><span class="section-number-4">2.6.2</span> CBCD</h4>
<div class="outline-text-4" id="text-2-6-2">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-right" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">Measurement</th>
<th scope="col" class="org-right">Value</th>
<th scope="col" class="org-right">Range</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left"><b>WBC</b></td>
<td class="org-right">20.5 K/uL</td>
<td class="org-right">4.5-11.0</td>
</tr>

<tr>
<td class="org-left"><b>RBC</b></td>
<td class="org-right">3.91 M/uL</td>
<td class="org-right">4.2-5.4</td>
</tr>

<tr>
<td class="org-left"><b>HEMOGLOBIN</b></td>
<td class="org-right">11.9 gm/dL</td>
<td class="org-right">12.0-16.0</td>
</tr>

<tr>
<td class="org-left"><b>HEMATOCRIT</b></td>
<td class="org-right">35.1%</td>
<td class="org-right">36-46</td>
</tr>

<tr>
<td class="org-left">MCV</td>
<td class="org-right">89.7 fL</td>
<td class="org-right">80-100</td>
</tr>

<tr>
<td class="org-left">MCH</td>
<td class="org-right">30.3 pg</td>
<td class="org-right">27-31</td>
</tr>

<tr>
<td class="org-left">MCHC</td>
<td class="org-right">33.8 g/dL</td>
<td class="org-right">31.0-37.0</td>
</tr>

<tr>
<td class="org-left">RDW</td>
<td class="org-right">14.1%</td>
<td class="org-right">11.5-14.5</td>
</tr>

<tr>
<td class="org-left">MPV</td>
<td class="org-right">7.5 fL</td>
<td class="org-right">7.4-10.4</td>
</tr>

<tr>
<td class="org-left">NEUT</td>
<td class="org-right">60.0</td>
<td class="org-right">15-75</td>
</tr>

<tr>
<td class="org-left">LYMPH</td>
<td class="org-right">29.0</td>
<td class="org-right">15-41</td>
</tr>

<tr>
<td class="org-left">MONO</td>
<td class="org-right">9.0%</td>
<td class="org-right">0-15</td>
</tr>

<tr>
<td class="org-left">EOS</td>
<td class="org-right">1.0%</td>
<td class="org-right">0-2.7</td>
</tr>

<tr>
<td class="org-left">BASO</td>
<td class="org-right">1.0%</td>
<td class="org-right">&#xa0;</td>
</tr>

<tr>
<td class="org-left"><b>Bands</b></td>
<td class="org-right">18% H</td>
<td class="org-right">0-8</td>
</tr>

<tr>
<td class="org-left">PLATELET</td>
<td class="org-right">236000</td>
<td class="org-right">150-440</td>
</tr>

<tr>
<td class="org-left">PROTIME</td>
<td class="org-right">20:01:00 on 21 Jan 2019</td>
<td class="org-right">&#xa0;</td>
</tr>

<tr>
<td class="org-left">PROTIME</td>
<td class="org-right">10.8</td>
<td class="org-right">9.4-12.5</td>
</tr>

<tr>
<td class="org-left">INR</td>
<td class="org-right">2.4</td>
<td class="org-right">2.5-3.5</td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="outline-container-orgb8809da" class="outline-4">
<h4 id="orgb8809da"><span class="section-number-4">2.6.3</span> ABG</h4>
<div class="outline-text-4" id="text-2-6-3">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">Measurement</th>
<th scope="col" class="org-left">Value</th>
<th scope="col" class="org-right">Ref. Range</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left">pH</td>
<td class="org-left">7.23</td>
<td class="org-right">7.35-7.45</td>
</tr>

<tr>
<td class="org-left">PCO<sub>2</sub></td>
<td class="org-left">61 mm Hg</td>
<td class="org-right">&#xa0;</td>
</tr>

<tr>
<td class="org-left">PCO<sub>2</sub></td>
<td class="org-left">73 mm Hg</td>
<td class="org-right">&#xa0;</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div id="outline-container-org4bbec6b" class="outline-3">
<h3 id="org4bbec6b"><span class="section-number-3">2.7</span> Diagnostics</h3>
<div class="outline-text-3" id="text-2-7">
<p>
Chest X-ray: Right middle and right lower lobe consolidative airspace disease, likely pneumonia. Left lung is clear. Heart size is normal.
</p>

<p>
Sputum gram stain: &gt;25 WBCs/hpf, &lt;10 epithelial cells/hpf, many Gram (+) cocci in pairs.
</p>

<p>
QTc: 490 ms
</p>

<p>
DIAGNOSIS: Probable multilobar community acquired pneumonia.
</p>
</div>
</div>
</div>
<div id="outline-container-org874ae66" class="outline-2">
<h2 id="org874ae66"><span class="section-number-2">3</span> Assessment</h2>
<div class="outline-text-2" id="text-3">
</div>
<div id="outline-container-org46fa2c1" class="outline-3">
<h3 id="org46fa2c1"><span class="section-number-3">3.1</span> Prioritized problems list</h3>
<div class="outline-text-3" id="text-3-1">
<ol class="org-ol">
<li>Community acquired pneumonia</li>
<li>COPD</li>
<li>Atrial fibrillation</li>
<li>Anxiety and depression</li>
</ol>
</div>
</div>
<div id="outline-container-orgbda9c9e" class="outline-3">
<h3 id="orgbda9c9e"><span class="section-number-3">3.2</span> Community acquired pneumonia (CAP)</h3>
<div class="outline-text-3" id="text-3-2">
<p>
The patient has all the primary characteristic symptoms of CAP: SOB, cough, fever, chills, and pleuritic chest pain. Chest X-ray reveals likely pneumoniae in the right middle and right lower lung lobes. Lab results are indicative of CAP. Elevated WBC count suggests a septic state.
</p>

<p>
The patient has multiple risk factors for drug-resistant <i>S. pneumoniae</i> due to her comorbidities.
</p>
<ul class="org-ul">
<li>COPD</li>
<li>concomitant antibiotic therapy</li>
<li>age &gt;65</li>
<li>atrial fibrillation</li>
</ul>

<p>
Her CURB-65 severity score is 3 owing to (1) being over 65, (2) having BUN ≥20 mg/dL, and (3) having a respiratory rate ≥30/minute. This correlates to an 11% mortality risk for which guidelines recommend inpatient treatment with intensive care admission (Ebell 2006). According to the <i>BMJ</i>, high glucose levels as seen in the patient are predictive of mortality, which is another reason to admit the patient to ICU.
</p>

<p>
Although serology and urine antigen testing are pending, it appears that the causative agent is <i>S. pneumoniae</i>, not <i>Pseudomonas</i> since Gram-(+) cocci were present in sputum. Because the patient did not respond to dual macrolide and β-lactam antibiotic therapy, the patient likely has multi-drug resistant <i>S. pneumoniae</i>. Without lab results for definitive therapy, we can only start empiric therapy with broad spectrum antibiotics recommended by guidelines for CAP.
</p>

<p>
The patient is at risk of Pseudomonal infection due to COPD and usage of fluticasone. Macrolides like azithromycin are recommended in this case (IDSA 2007 guidelines).
</p>

<p>
Respiratory fluoroquinolones are recommended for inpatient treatment of CAP (strong recommendation, level 1 evidence). Fluoroquinolones have favorable PK and potency, have favorable potency, and can be conveniently administered orally in addition to IV.
</p>

<p>
<b>Goals</b>:
</p>
<ul class="org-ul">
<li>Achieve clearance of CAP</li>
<li>Avoid mortality due to CAP</li>
</ul>
</div>
</div>
<div id="outline-container-org6f696ba" class="outline-3">
<h3 id="org6f696ba"><span class="section-number-3">3.3</span> COPD</h3>
<div class="outline-text-3" id="text-3-3">
<p>
She has a previous diagnosis of moderate COPD. In June 2018, her FEV1/FVC (forced expiratory volume : forced vital capacity) was 71%, meeting the criteria for moderate COPD. Her respiratory symptoms such as dyspnea overlap with those of CAP, so it is difficult to pinpoint any COPD-specific symptoms.
</p>

<p>
<b>Goals</b>:
</p>
<ul class="org-ul">
<li>Relieve symptoms</li>
<li>Improve exercise tolerance and general health</li>
<li>Prevent exacerbations and hospitalizations</li>
<li>Reduce mortality</li>
</ul>
</div>
</div>
<div id="outline-container-orgdfb4e1e" class="outline-3">
<h3 id="orgdfb4e1e"><span class="section-number-3">3.4</span> Atrial fibrillation</h3>
<div class="outline-text-3" id="text-3-4">
<p>
The patient has a previous diagnosis of atrial fibrillation. Physical examination showed that she has signs of atrial fibrillation: tachycardia, abnormal rate and rhythm, audible S<sub>1</sub> and S<sub>2</sub>, and QT prolongation.
</p>

<p>
Amiodarone is also known to have a drug interaction with azithromycin, which contributes to the patient’s prolonged QT interval of 490 ms.
</p>

<p>
The patient is taking amiodarone for atrial fibrillation, but amiodarone has a drug interaction with levofloxacin&#x2014;enhancing the QT-prolonging effect of amiodarone.
</p>

<p>
<b>Goals</b>: Prevent stroke and reduce mortality
</p>
</div>
</div>
<div id="outline-container-orge33627d" class="outline-3">
<h3 id="orge33627d"><span class="section-number-3">3.5</span> Anxiety and depression</h3>
<div class="outline-text-3" id="text-3-5">
<p>
The patient has a previous diagnosis of anxiety and depression. In review of systems, it is noted that the patient appeared somewhat anxious, in line with this diagnosis.
</p>

<p>
<b>Goals</b>: Promote well-being
</p>
</div>
</div>
</div>
<div id="outline-container-orga292a80" class="outline-2">
<h2 id="orga292a80"><span class="section-number-2">4</span> Plan</h2>
<div class="outline-text-2" id="text-4">
</div>
<div id="outline-container-org5095bf2" class="outline-3">
<h3 id="org5095bf2"><span class="section-number-3">4.1</span> CAP</h3>
<div class="outline-text-3" id="text-4-1">
</div>
<div id="outline-container-org848d5b6" class="outline-4">
<h4 id="org848d5b6"><span class="section-number-4">4.1.1</span> Non-pharmacologic</h4>
<div class="outline-text-4" id="text-4-1-1">
<p>
Oxygen via nasal cannula
</p>
</div>
</div>
<div id="outline-container-org24b4593" class="outline-4">
<h4 id="org24b4593"><span class="section-number-4">4.1.2</span> Pharmacologic</h4>
<div class="outline-text-4" id="text-4-1-2">
<ul class="org-ul">
<li>Initiate <b>Levofloxacin 750 mg</b> IV for inpatient treatment then switching to 750 mg PO for 7 days</li>
<li>Continue Azithromycin 250 mg PO QD</li>
<li>Discontinue Amoxicillin-Clavulanate 875mg-125 mg BID</li>
<li>Temporarily discontinue Amiodarone 100 mg PO QD because of drug interaction with levofloxacin</li>
</ul>
</div>
</div>
<div id="outline-container-orgc9321c3" class="outline-4">
<h4 id="orgc9321c3"><span class="section-number-4">4.1.3</span> Monitoring</h4>
<div class="outline-text-4" id="text-4-1-3">
</div>
<ol class="org-ol">
<li><a id="org2d62b54"></a>for efficacy<br />
<div class="outline-text-5" id="text-4-1-3-1">
<ul class="org-ul">
<li>CBC with differential&#x2014;normal CBC counts are indicative of efficacy</li>
<li>Temperature</li>
</ul>
</div>
</li>
<li><a id="org0ce71b1"></a>for safety<br />
<div class="outline-text-5" id="text-4-1-3-2">
<ul class="org-ul">
<li>liver function tests</li>
<li>CBC with differential</li>
<li>s/s tendonitis</li>
</ul>
</div>
</li>
</ol>
</div>
<div id="outline-container-orgbec179f" class="outline-4">
<h4 id="orgbec179f"><span class="section-number-4">4.1.4</span> Adverse effects</h4>
<div class="outline-text-4" id="text-4-1-4">
<ul class="org-ul">
<li>nausea</li>
<li>vomiting</li>
<li>diarrhea</li>
<li>headache</li>
</ul>
</div>
</div>
<div id="outline-container-org8d08af3" class="outline-4">
<h4 id="org8d08af3"><span class="section-number-4">4.1.5</span> Counseling</h4>
<div class="outline-text-4" id="text-4-1-5">
<ul class="org-ul">
<li>Immediately report symptoms of tendon swelling or tendonitis</li>
<li>Report symptoms of peripheral neuropathy such as tingling or numbness in extremities</li>
<li>Report symptoms of QT prolongation&#x2014;tachycardia, convulsions, or intracranial pressure</li>
<li>Consult healthcare professional before using new drugs or OTC drugs/supplements because of numerous drug interactions with the quinolone antibiotic</li>
<li>CAP may take several weeks to resolve. Fever should resolve within 3 days, followed by cough, and finally clearance on chest X-ray after 2 or more weeks.</li>
</ul>
</div>
</div>
<div id="outline-container-org782b86e" class="outline-4">
<h4 id="org782b86e"><span class="section-number-4">4.1.6</span> Follow-up</h4>
<div class="outline-text-4" id="text-4-1-6">
<ul class="org-ul">
<li>Take new chest X-ray after 7 days.</li>
<li>Check new labs.</li>
<li>If symptoms aren’t resolved or pneumonia remains uncleared on in the chest X-ray, then extend pharmacologic therapy with follow-up every 3 weeks until radiographic clearance.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org987b0fe" class="outline-3">
<h3 id="org987b0fe"><span class="section-number-3">4.2</span> COPD</h3>
<div class="outline-text-3" id="text-4-2">
</div>
<div id="outline-container-org0f4c375" class="outline-4">
<h4 id="org0f4c375"><span class="section-number-4">4.2.1</span> Pharmacologic</h4>
<div class="outline-text-4" id="text-4-2-1">
<ul class="org-ul">
<li>Continue Albuterol 1 puff QID as needed</li>
<li>Continue Salmeterol-Fluticasone DPI 50/250 1 puff BID</li>
</ul>
</div>
</div>
<div id="outline-container-org337934c" class="outline-4">
<h4 id="org337934c"><span class="section-number-4">4.2.2</span> Adverse effects</h4>
<div class="outline-text-4" id="text-4-2-2">
<ul class="org-ul">
<li>nausea</li>
<li>oral candidiasis</li>
</ul>
</div>
</div>
<div id="outline-container-orgc8e549e" class="outline-4">
<h4 id="orgc8e549e"><span class="section-number-4">4.2.3</span> Monitoring</h4>
<div class="outline-text-4" id="text-4-2-3">
</div>
<ol class="org-ol">
<li><a id="orgdc1662e"></a>for efficacy<br />
<div class="outline-text-5" id="text-4-2-3-1">
<p>
reduction in asthma symptoms
</p>
</div>
</li>
<li><a id="org91a5026"></a>for safety<br />
<div class="outline-text-5" id="text-4-2-3-2">
<p>
renal function; especially important in elderly patients
</p>
</div>
</li>
</ol>
</div>
<div id="outline-container-org91006ee" class="outline-4">
<h4 id="org91006ee"><span class="section-number-4">4.2.4</span> Counseling</h4>
<div class="outline-text-4" id="text-4-2-4">
<ul class="org-ul">
<li>Report symptoms of bronchospasm.</li>
<li>Rinse mouth (do not swallow) after using fluticasone-salmeterol to avoid candidiasis.</li>
<li>Ensure patient knows proper inhalation technique.</li>
<li>Take fluticasone-salmeterol on a consistent schedule.</li>
</ul>
</div>
</div>
<div id="outline-container-orgfcd2cdb" class="outline-4">
<h4 id="orgfcd2cdb"><span class="section-number-4">4.2.5</span> Follow-up</h4>
<div class="outline-text-4" id="text-4-2-5">
<p>
Ask the patient about any changes in the frequency of use or number of inhalations of albuterol.
</p>
</div>
</div>
</div>
<div id="outline-container-orgeeee959" class="outline-3">
<h3 id="orgeeee959"><span class="section-number-3">4.3</span> Atrial fibrillation</h3>
<div class="outline-text-3" id="text-4-3">
</div>
<div id="outline-container-orge0bf462" class="outline-4">
<h4 id="orge0bf462"><span class="section-number-4">4.3.1</span> Pharmacologic</h4>
<div class="outline-text-4" id="text-4-3-1">
<ul class="org-ul">
<li>Discontinue <b>Amiodarone 100 mg PO QD</b> until the cessation of antibiotic therapy, then restart</li>
<li>Replace amiodarone with <b>Metoprolol succinate ER 50 mg PO QD</b> until cessation of antibiotic therapy, then discontinue</li>
<li>Continue <b>Warfarin (Coumadin®) 2.5 mg MWF and 1.25 mg TTSS</b></li>
</ul>
</div>
</div>
<div id="outline-container-org931a36d" class="outline-4">
<h4 id="org931a36d"><span class="section-number-4">4.3.2</span> Adverse effects</h4>
<div class="outline-text-4" id="text-4-3-2">
</div>
<ol class="org-ol">
<li><a id="orgeb6a85a"></a>amiodarone<br />
<div class="outline-text-5" id="text-4-3-2-1">
<ul class="org-ul">
<li>photosensitivity</li>
<li>constipation</li>
<li>loss of appetite</li>
<li>nausea, vomiting</li>
</ul>
</div>
</li>
<li><a id="org39e442d"></a>warfarin<br />
<div class="outline-text-5" id="text-4-3-2-2">
<ul class="org-ul">
<li>bleeding</li>
<li>tissue necrosis</li>
<li>hemorrhage</li>
</ul>
</div>
</li>
<li><a id="org0b8e24f"></a>metoprolol<br />
<div class="outline-text-5" id="text-4-3-2-3">
<ul class="org-ul">
<li>bradycardia</li>
<li>bronchospasm</li>
</ul>
</div>
</li>
</ol>
</div>
<div id="outline-container-org197f97d" class="outline-4">
<h4 id="org197f97d"><span class="section-number-4">4.3.3</span> Monitoring</h4>
<div class="outline-text-4" id="text-4-3-3">
</div>
<ol class="org-ol">
<li><a id="org22b2ce9"></a>for safety<br />
<div class="outline-text-5" id="text-4-3-3-1">
<ul class="org-ul">
<li>Monitor bleeding and INR very carefully as levofloxacin interacts with warfarin to enhance its anticoagulant effect.</li>
<li>Monitor ECG and QTc interval</li>
</ul>
</div>
</li>
<li><a id="orgcd21a0a"></a>for efficacy<br />
<div class="outline-text-5" id="text-4-3-3-2">
<ul class="org-ul">
<li>INR</li>
<li>HR</li>
<li>BP</li>
</ul>
</div>
</li>
</ol>
</div>
<div id="outline-container-org0aff5cb" class="outline-4">
<h4 id="org0aff5cb"><span class="section-number-4">4.3.4</span> Counseling</h4>
<div class="outline-text-4" id="text-4-3-4">
<ul class="org-ul">
<li>Maintain consistent weekly consumption of vitamin K-rich green leafy vegetables or green tea.</li>
<li>Immediately report symptoms of major bleeding.</li>
<li>Take a missed dose if remembered on the same day. If an entire day has passed, skip the dose and resume normal schedule.</li>
<li>Wear helmets and keep safe from falling as it would be much more dangerous on warfarin.</li>
<li>Let all healthcare professionals know about warfarin medication.</li>
<li>Seek emergency medical attention for any life-threatening symptoms of atrial fibrillation such as syncope, confusion, or heart rate over 200/minute.</li>
</ul>
</div>
</div>
<div id="outline-container-orgaf519ff" class="outline-4">
<h4 id="orgaf519ff"><span class="section-number-4">4.3.5</span> Follow-up</h4>
<div class="outline-text-4" id="text-4-3-5">
<p>
On next visit, check whether ventricular rate/rhythm is controlled and whether atrial fibrillation persists.
</p>
</div>
</div>
</div>
<div id="outline-container-org2aff6ab" class="outline-3">
<h3 id="org2aff6ab"><span class="section-number-3">4.4</span> Anxiety and depression</h3>
<div class="outline-text-3" id="text-4-4">
</div>
<div id="outline-container-orgc8dc7a3" class="outline-4">
<h4 id="orgc8dc7a3"><span class="section-number-4">4.4.1</span> Pharmacologic</h4>
<div class="outline-text-4" id="text-4-4-1">
<p>
Continue Venlafaxine 75 mg PO AM
</p>
</div>
</div>
<div id="outline-container-org2705a8e" class="outline-4">
<h4 id="org2705a8e"><span class="section-number-4">4.4.2</span> Adverse effects</h4>
<div class="outline-text-4" id="text-4-4-2">
<ul class="org-ul">
<li>sweating</li>
<li>constipation</li>
<li>hypertension</li>
</ul>
</div>
</div>
<div id="outline-container-orgfa1418a" class="outline-4">
<h4 id="orgfa1418a"><span class="section-number-4">4.4.3</span> Monitoring</h4>
<div class="outline-text-4" id="text-4-4-3">
</div>
<ol class="org-ol">
<li><a id="orgf86e8c3"></a>for efficacy<br />
<div class="outline-text-5" id="text-4-4-3-1">
<p>
Stability of symptoms
</p>
</div>
</li>
<li><a id="org7651f91"></a>for safety<br />
<div class="outline-text-5" id="text-4-4-3-2">
<ul class="org-ul">
<li>cholesterol; fasting lipid panel</li>
<li>serum sodium levels</li>
<li>renal function (suggested for elderly patients)</li>
</ul>
</div>
</li>
</ol>
</div>
<div id="outline-container-orge5f7043" class="outline-4">
<h4 id="orge5f7043"><span class="section-number-4">4.4.4</span> Counseling</h4>
<div class="outline-text-4" id="text-4-4-4">
<ul class="org-ul">
<li>Take with food</li>
<li>Do not drink alcohol while taking this drug</li>
<li>Advise the patient against sudden discontinuation of venlafaxine because doing so may precipitate withdrawal symptoms</li>
</ul>
</div>
</div>
<div id="outline-container-orgeb38c4f" class="outline-4">
<h4 id="orgeb38c4f"><span class="section-number-4">4.4.5</span> Follow-up</h4>
<div class="outline-text-4" id="text-4-4-5">
<p>
Check for worsening of anxiety or depression or unusual changes in behavior. Healthcare professionals should maintain at least weekly face-to-face contact with the patient, her family members, or her caregivers.
</p>
</div>
</div>
</div>
</div>
</div>
<div id="postamble" class="status">
<p class="author">Author: zds</p>
<p class="date">Created: 2019-01-20 Sun 23:05</p>
<p class="validation"><a href="http://validator.w3.org/check?uri=referer">Validate</a></p>
</div>
</body>
</html>
